I think a few people might have missed the importance of RxCell...

I think a few people might have missed the importance of RxCell in IPSC's. I never saw this collaboration coming and surprisingly meets a left field ambition I held. Happily picked up more stock lower. Those of us who odn't just make pointless aimless comments on these micro-caps, realise there is already a $2 billion USD capped company offering FDA approved scaffold/stem-cell combination treatments to patients in the US (ironically on original Aussie autologous stem cell technology).

RxCell is well progressed with a likely 2 year IND at the FDA and funnily enough is a potential competitor for another company I was recently (succesfully) invested in AMD markets with:

https://www.businesswire.com/news/home/20240917652923/en/RxCell-Inc.-Granted-U.S.-Patent-for-iPSC-based-Cell-Therapy

And is already the benificary of Singapore funding interest:

https://www.businesswire.com/news/home/20231205727354/en/RxCell-Announces-4600000-Investment-from-DMR-Global-Venture-and-Regenosis-Plans-for-Second-Raise-of-15000000-for-IND-Testing-in-Q4-2023

3-D printed bio-absorble polymer scaffolds augmented by stem cells? Yes please. Contrary to popular notions, the FDA has approved plenty of autologous stem cell therapies (in blood cancers) and the first allogeneic may be early next quarter (yet another Aussie company). IPSC's naturally the next frontier to meet preceived scale and consitency issues with standard donor MSC's.

Lets hope the next announcement sees some funding attached.